证券代码：688062 证券简称：迈威生物 公告编号：2026-001 迈威（上海）生物科技股份有限公司 关于预计 2026 年度日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 是否需要提交股东会审议：否 日常关联交易对上市公司的影响：公司预计的 2026 年日常关联交易，是 基于公司和关联方之间的正常生产经营需要进行。关联交易遵循公平合理的定价 原则，不存在损害公司及股东特别是中小股东利益的情形，公司对关联方也不会 形成依赖，也不会影响公司的独立性。公司与上述关联人保持较为稳定的合作关 系，在公司业务存在切实需求的情况下，与上述关联人之间的关联交易将持续存 在。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 1、公司董事会审计委员会审议程序 公司于2026年1月16日召开第二届董事会审计委员会第二十次会议，通过了 《关于预计2026年度日常关联交易的议案》，并同意将该议案提交至公司董事会 审议。 2、公司董事会审议程序 公司于2026年1月21日召开第二届董事会第二十七次 ...

投资种类：安全性高、流动性好、有保本约定的投资产品（包括但不限 于结构性存款、通知存款、定期存款、大额存单、协定存款等） 证券代码：688062 证券简称：迈威生物 公告编号：2026-002 迈威（上海）生物科技股份有限公司 关于继续使用部分暂时闲置募集资金进行现金管理 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资金额：不超过人民币 8 亿元（含本数） 已履行的审议程序：迈威（上海）生物科技股份有限公司（以下简称"迈 威生物"或"公司"）于 2026 年 1 月 21 日召开第二届董事会第二十七次会议， 审议通过了《关于继续使用部分暂时闲置募集资金进行现金管理的议案》，该事 项在公司董事会审批权限范围内，无需提交股东会审议。保荐机构国泰海通证券 股份有限公司对上述事项出具了明确同意的核查意见。 特别风险提示：尽管公司选择低风险投资品种的现金管理产品，但金融 市场主要受货币政策等宏观经济的影响，公司将根据经济形势以及金融市场的变 化适时适量的介入，但不排除该项投资受到市场波动的影响。 一、投资情 ...

南财智讯1月21日电，迈威生物公告，公司于2026年1月21日召开第二届董事会第二十七次会议，审议通 过了《关于继续使用部分暂时闲置募集资金进行现金管理的议案》。公司及全资子公司拟使用最高不超 过8.00亿元的暂时闲置募集资金进行现金管理，在额度及使用期限范围内资金可滚动使用，有效期自董 事会审议通过之日起12个月内有效。投资方向为购买安全性高、流动性好、有保本约定的投资产品，包 括但不限于结构性存款、通知存款、定期存款、大额存单、协定存款等。公司强调，该事项不会影响募 集资金投资项目进度和公司正常生产经营。 ...

东方创新医疗股票A（018045）成立日期2023年5月8日，最新规模1070.2万。今年以来收益8.85%，同 类排名1479/5542；近一年收益34.05%，同类排名2266/4235；成立以来收益8.43%。 东方创新医疗股票A（018045）基金经理为蔡尚军。 截至发稿，蔡尚军累计任职时间1年335天，现任基金资产总规模5488.34万元，任职期间最佳基金回报 10.94%， 任职期间最差基金回报1.41%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 1月20日，迈威生物跌5%，截至发稿，报39.88元/股，成交2.72亿元，换手率3.28%，总市值159.36亿 元。 资料显示，迈威(上海)生物科技股份有限公司位于中国(上海)自由贸易试验区蔡伦路230号2幢105室香港 铜锣湾希慎道33号利园1期19楼1928室，成立日期2017年5月12日，上市日期2022年1月18日，公司主营 业务涉及治疗用生物制品的研发、生产与销售。主营业务收入构成为：销售商品9 ...

Core Viewpoint - Maiwei Biotech's stock has shown volatility with a recent increase of 2.03%, but has experienced a decline of 6.71% over the past five trading days, indicating mixed market sentiment [1] Group 1: Stock Performance - As of January 16, Maiwei Biotech's stock price is 42.70 CNY per share, with a market capitalization of 17.063 billion CNY [1] - The stock has increased by 11.00% year-to-date, but has seen a decline of 4.37% over the past 60 days [1] - Trading volume on January 16 reached 2.31 million CNY, with a turnover rate of 2.71% [1] Group 2: Financial Performance - For the period from January to September 2025, Maiwei Biotech reported revenue of 566 million CNY, reflecting a year-on-year growth of 301.03% [2] - The company recorded a net profit attributable to shareholders of -598 million CNY, which is a year-on-year increase of 13.89% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders has increased by 9.15% to 19,600, while the average number of circulating shares per person has decreased by 8.38% to 10,425 shares [2] - Notable institutional shareholders include E Fund Medical Healthcare Industry Mixed A, which is the fourth largest shareholder with 3.1746 million shares, and South China CSI 1000 ETF, which is a new entrant among the top ten shareholders [2]

Core Viewpoint - The innovative drug sector is experiencing a decline, with several key stocks and ETFs showing significant drops in value, indicating a potential shift in market sentiment towards this industry [1][2]. Group 1: Stock Performance - Rongchang Biopharmaceutical has seen a decline of over 10% in its stock price [1]. - Other companies such as Baile Tianheng, Xinlitai, and Maiwei Biopharmaceutical-U have also dropped more than 3% [1]. - Multiple innovative drug-related ETFs have decreased nearly 2% in value [1]. Group 2: Market Analysis - Some brokerages suggest that core assets in the innovative drug sector will continue to appreciate, highlighting emerging opportunities in small nucleic acids and in vivo CAR technologies [2]. - The long-term trend of innovative drug business development (BD) is seen as a pathway for Chinese innovative drug capabilities to gain recognition on the global stage [2]. - Core assets that have been licensed to multinational corporations (MNCs) are expected to realize their value as clinical progress continues [2]. - Future focus should remain on cutting-edge technology platforms and closely monitor advancements in clinical data [2].

证券日报网讯 1月9日，迈威生物在互动平台回答投资者提问时表示，二级市场的股价受多重因素影 响，迈威生物对公司股票在二级市场的价格表现保持关注，并致力于发展主营业务，为股东提供更好的 投资回报。 （文章来源：证券日报） ...

Core Viewpoint - The company has established strategic partnerships with leading AI firms, DeepMind Technology and Insilico Medicine, to leverage AI technology in drug development and optimize biopharmaceuticals [1] Group 1: AI Integration in Drug Development - The company is utilizing multi-omics analysis and AI techniques to discover new targets and target combinations [1] - AI and genetic engineering are being combined to optimize and modify antibody molecules and ADC (Antibody-Drug Conjugate) molecules [1] - AI technology is being employed in the ADC field to assist in the structural design of new mechanism toxins and improve drug developability [1] Group 2: Commitment to Innovation - The company is actively promoting the deep integration of biomedicine and AI technology to empower innovative drug research and development [1] - The goal is to provide patients with more effective and accessible biopharmaceutical innovations, addressing unmet clinical needs globally [1]

Core Viewpoint - The A-share market is experiencing a significant upward trend, with the Shanghai Composite Index returning to 4100 points for the first time in 10 years, driven by a strong performance in the innovative pharmaceutical sector, particularly the Sci-Tech Innovation Drug ETF Huatai (589120) which rose over 3% [1] Group 1: Market Performance - The Sci-Tech Innovation Drug ETF Huatai (589120) saw most of its constituent stocks surge, with notable increases such as Yuekang Pharmaceutical up over 10%, Zhixiang Jintai up over 8%, and Micron Biologics up over 6% [3] - The top ten constituent stocks of the ETF include major players in the pharmaceutical sector, with BeiGene (688235) rising by 1.77% and Aier Eye Hospital (688578) increasing by 2.18% [3] Group 2: Regulatory Support - A national drug supervision conference held from January 6 to 7 emphasized the need to actively support the pharmaceutical industry in enhancing quality and efficiency, alongside comprehensive reforms in drug regulation [4] Group 3: Innovation and Drug Approvals - Innovation remains a key theme in the Sci-Tech Innovation Drug sector, with recent announcements including Zhixiang Jintai's conditional listing application for a dual-antibody drug and Micron Biologics receiving approval for clinical trials of a new drug for pancreatic cancer [5] - BeiGene announced the conditional approval of its new BCL2 inhibitor, providing new treatment options for patients with chronic lymphocytic leukemia [6] - Rongchang Biologics is seeking breakthrough therapy designation for a new indication of its drug, which would mark a significant regulatory achievement for domestic ADC products [7] Group 4: Future Outlook - The Pacific Securities report anticipates that by 2026, the innovative drug sector will benefit from enhanced international capabilities and supportive industry policies, leading to increased market confidence and investment [8] - The report highlights that the average deal value for innovative drugs purchased from China by top multinational corporations is significantly higher than those from overseas, indicating a growing recognition of the value of Chinese innovative drugs in the global market [9]

Core Insights - The Chinese innovative pharmaceutical industry is undergoing a historic transformation, shifting from "fast followers" to "original creators" supported by solid data and market performance [1] - By 2025, the total value of innovative drug licensing transactions in China is expected to exceed $130 billion, with over 150 transactions, marking a historical high [1] - Shanghai's Pudong district is becoming a key hub for the global market, with significant achievements in CAR-T products and first-class new drugs [1] Industry Overview - China's pharmaceutical industry ranks second globally, with approximately 30% of innovative drugs in development worldwide [1] - The industry is entering a critical phase characterized by "innovation realization + global layout" [1] Company Developments - Chinese innovative drug companies are leveraging speed and cost-effectiveness to gain a competitive edge in the global market [3] - Companies like Maiwei Biotech and Jinsai Pharmaceutical are forming significant overseas business development (BD) partnerships, enhancing China's global competitiveness [3][4] - Maiwei Biotech has accelerated its BD efforts, securing exclusive licensing agreements for innovative therapies, including a $1 billion potential deal with Aditum Bio [4][5] Market Trends - By 2025, Pudong is expected to have approved four CAR-T products, accounting for 30% of the global total, and seven first-class new drugs, representing 14% of the national total [1] - The commercial sales of innovative drugs in Pudong are projected to exceed 11.6 billion yuan in 2024, with several new drugs achieving over 1 billion yuan in annual sales [10] Strategic Initiatives - Companies are focusing on building comprehensive global capabilities covering research, registration, and sales to transition from "licensing out" to "commercialization abroad" [10] - Jinsai Pharmaceutical has established local teams in the U.S. and Europe to manage clinical trials and seek collaboration opportunities [8] Innovation and Collaboration - The future of innovative drugs lies in international markets, with companies emphasizing deep understanding of disease biology as a core competitive advantage [5] - Companies are forming cooperative committees with BD partners to ensure project progress through information sharing and resource collaboration [5] Ecosystem Support - The rise of China's innovative drug industry is attributed to years of policy guidance, technological accumulation, and capital cultivation [23] - The unique industrial atmosphere, talent pool, and complete industrial chain in Zhangjiang are seen as core advantages for local companies [23][24] - Pudong's talent policies and supportive platforms are facilitating the rapid gathering of global talent resources [23] Future Outlook - The next 3-5 years are expected to see continued emphasis on internationalization and globalization among Chinese biopharmaceutical companies [14] - Companies are increasingly focusing on source innovation and high-quality BD potential to meet global market demands and achieve high valuations [17]